Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Dow
Medtronic
Moodys
Merck

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR FASLODEX


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Faslodex

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT00099437 ↗ Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. Active, not recruiting AstraZeneca Phase 3 2005-02-08 The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment
New Dosage NCT01300351 ↗ Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women Completed AstraZeneca Phase 3 2011-03-01 The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Faslodex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006903 ↗ Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Unknown status AstraZeneca Phase 2 2004-08-30 This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.
NCT00006903 ↗ Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Unknown status National Cancer Institute (NCI) Phase 2 2004-08-30 This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.
NCT00006903 ↗ Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Unknown status Gynecologic Oncology Group Phase 2 2004-08-30 This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.
NCT00010153 ↗ ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer Terminated Breast International Group Phase 3 2000-11-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases. PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer.
NCT00010153 ↗ ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer Terminated European Organisation for Research and Treatment of Cancer - EORTC Phase 3 2000-11-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases. PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Faslodex

Condition Name

Condition Name for Faslodex
Intervention Trials
Breast Cancer 53
Metastatic Breast Cancer 27
Advanced Breast Cancer 12
Breast Neoplasms 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Faslodex
Intervention Trials
Breast Neoplasms 129
Neoplasms 13
Carcinoma 12
Carcinoma, Non-Small-Cell Lung 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Faslodex

Trials by Country

Trials by Country for Faslodex
Location Trials
United States 650
Italy 80
Spain 77
Canada 50
Japan 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Faslodex
Location Trials
California 38
Texas 35
Florida 31
New York 30
Massachusetts 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Faslodex

Clinical Trial Phase

Clinical Trial Phase for Faslodex
Clinical Trial Phase Trials
Phase 4 2
Phase 3 26
Phase 2/Phase 3 1
[disabled in preview] 92
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Faslodex
Clinical Trial Phase Trials
Completed 58
Active, not recruiting 26
Recruiting 25
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Faslodex

Sponsor Name

Sponsor Name for Faslodex
Sponsor Trials
AstraZeneca 47
National Cancer Institute (NCI) 19
Pfizer 18
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Faslodex
Sponsor Trials
Other 136
Industry 128
NIH 20
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Harvard Business School
McKesson
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.